36,419 Shares in IVERIC bio, Inc. (NASDAQ:ISEE) Bought by Chartwell Investment Partners LLC

Chartwell Investment Partners LLC acquired a new position in shares of IVERIC bio, Inc. (NASDAQ:ISEEGet Rating) during the third quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm acquired 36,419 shares of the company’s stock, valued at approximately $654,000.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Captrust Financial Advisors grew its position in IVERIC bio by 14,900.0% in the first quarter. Captrust Financial Advisors now owns 1,500 shares of the company’s stock valued at $25,000 after purchasing an additional 1,490 shares in the last quarter. Vectors Research Management LLC bought a new position in IVERIC bio in the second quarter valued at $29,000. Nisa Investment Advisors LLC grew its position in IVERIC bio by 39.9% in the second quarter. Nisa Investment Advisors LLC now owns 4,520 shares of the company’s stock valued at $43,000 after purchasing an additional 1,290 shares in the last quarter. Macquarie Group Ltd. grew its position in IVERIC bio by 679.5% in the second quarter. Macquarie Group Ltd. now owns 8,005 shares of the company’s stock valued at $77,000 after purchasing an additional 6,978 shares in the last quarter. Finally, Amundi bought a new position in IVERIC bio in the second quarter valued at $102,000.

Insider Buying and Selling

In related news, COO Keith Westby sold 72,916 shares of IVERIC bio stock in a transaction dated Tuesday, November 1st. The shares were sold at an average price of $23.92, for a total transaction of $1,744,150.72. Following the completion of the sale, the chief operating officer now owns 69,128 shares of the company’s stock, valued at approximately $1,653,541.76. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. In other IVERIC bio news, COO Keith Westby sold 72,916 shares of IVERIC bio stock in a transaction dated Tuesday, November 1st. The shares were sold at an average price of $23.92, for a total value of $1,744,150.72. Following the completion of the sale, the chief operating officer now owns 69,128 shares in the company, valued at approximately $1,653,541.76. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Glenn Sblendorio sold 50,000 shares of IVERIC bio stock in a transaction dated Wednesday, November 2nd. The stock was sold at an average price of $23.01, for a total transaction of $1,150,500.00. Following the completion of the sale, the chief executive officer now owns 179,689 shares of the company’s stock, valued at approximately $4,134,643.89. The disclosure for this sale can be found here. In the last 90 days, insiders sold 201,050 shares of company stock valued at $4,545,066. Company insiders own 2.70% of the company’s stock.

IVERIC bio Stock Performance

Shares of ISEE stock opened at $19.76 on Monday. The company has a quick ratio of 13.40, a current ratio of 13.40 and a debt-to-equity ratio of 0.18. The company has a 50-day simple moving average of $21.29 and a 200 day simple moving average of $16.96. IVERIC bio, Inc. has a 52 week low of $8.85 and a 52 week high of $24.33.

IVERIC bio (NASDAQ:ISEEGet Rating) last announced its earnings results on Thursday, November 3rd. The company reported ($0.35) EPS for the quarter, topping the consensus estimate of ($0.40) by $0.05. As a group, equities analysts forecast that IVERIC bio, Inc. will post -1.43 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of research firms recently weighed in on ISEE. HC Wainwright raised their target price on shares of IVERIC bio from $26.00 to $35.00 and gave the company a “buy” rating in a research report on Friday, November 4th. B. Riley raised shares of IVERIC bio from a “sell” rating to a “neutral” rating in a research report on Monday, October 17th. Jefferies Financial Group downgraded shares of IVERIC bio from a “buy” rating to a “hold” rating and decreased their price objective for the company from $30.00 to $20.00 in a research report on Thursday, November 10th. Finally, StockNews.com raised shares of IVERIC bio to a “sell” rating in a research report on Wednesday, October 5th. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and seven have issued a buy rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $26.20.

IVERIC bio Company Profile

(Get Rating)

IVERIC bio, Inc, a biopharmaceutical company, discovers and develops novel treatments for retinal diseases with a focus on age-related and orphan inherited retinal diseases (IRDs). The company develops Zimura, an inhibitor of complement factor C5 comprising GATHER1, which has completed Phase 2/3 clinical trial; and GATHER2 that is in Phase 3 clinical trial for the treatment of geographic atrophy (GA) secondary to dry age-related macular degeneration (AMD).

See Also

Want to see what other hedge funds are holding ISEE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for IVERIC bio, Inc. (NASDAQ:ISEEGet Rating).

Institutional Ownership by Quarter for IVERIC bio (NASDAQ:ISEE)

Receive News & Ratings for IVERIC bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IVERIC bio and related companies with MarketBeat.com's FREE daily email newsletter.